Bibliometric analysis of organoids in regenerative medicine-related research worldwide over two decades (2002-2022).

IF 2.4 4区医学 Q4 CELL & TISSUE ENGINEERING Regenerative medicine Pub Date : 2024-03-01 Epub Date: 2024-03-07 DOI:10.2217/rme-2023-0176

Jajar Setiawan, Dicky Moch Rizal, Fajar Sofyantoro, Dwi Sendi Priyono, Nur Indah Septriani, Wulan Usfi Mafiroh, Takenori Kotani, Takashi Matozaki, Wahyu Aristyaning Putri

引用次数: 0

Abstract

Aim: This study aimed to evaluate the trends in organoid culture research within the field of regenerative medicine from 2002 to 2022. Methods: The worldwide distribution of organoid research in regenerative medicine articles indexed in the Scopus database was analyzed. Result: A total of 840 documents were analyzed, averaging 42 publications annually. The USA (n = 296) led in publications, followed by China (n = 127), Japan (n = 91) and the UK (n = 75). Since 2011, research has surged, particularly in China, which emerged as a prominent center. Conclusion: The findings highlight significant growth in organoid research, promising future organ transplantation. Research trends integrate tissue engineering, gene modification and induced pluripotent stem cell technologies, reflecting a move toward personalized medicine.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

二十年来（2002-2022 年）全球再生医学相关研究中有机体的文献计量分析。

目的：本研究旨在评估 2002 年至 2022 年再生医学领域的类器官培养研究趋势。研究方法分析了 Scopus 数据库收录的再生医学领域类器官研究文章的全球分布情况。结果：共分析了 840 篇文献：共分析了 840 篇文献，平均每年 42 篇。美国（296 篇）的论文数量居首，其次是中国（127 篇）、日本（91 篇）和英国（75 篇）。自 2011 年以来，研究数量激增，尤其是中国，已成为一个突出的研究中心。结论研究结果凸显了类器官研究的显著增长，为未来的器官移植带来了希望。研究趋势整合了组织工程、基因修饰和诱导多能干细胞技术，反映了向个性化医学发展的趋势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.